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Introduction
The efficacy of biological therapies currently used in
psoriatic arthritis depends not only on their blocking
effect on the targeted molecule but also on the affinity
of genetically defined variants of the Fc-gamma recep-
tors for the constant portion (Fc fragment of IgG1).
Aim
To determine whether polymorphisms in Fc-gamma
receptor IIA influence clinical efficacy in patients with
psoriatic arthritis treated with tumor necrosis factor
alpha inhibitors.
Patients and methods
The study population comprised 110 patients (52.7%
males and 47.3% females) with psoriatic arthritis refrac-
tory to 15 mg or more of methotrexate/week. Infliximab
(33.6%), etanercept (50.9%) or adalimumab (15.5%) were
initiated, and patients were evaluated after 12 and
24 weeks using the EULAR response criteria. Genotyping
of FCGR IIA-H131R polymorphism was performed by
allele-specific PCR and PCR sequence-based typing. The
chi-square test was used to compare response rates
across Fc-gamma receptor IIA genotype.
Results
No significant differences were found at 12 and 24
weeks in EULAR responses between patients with high
affinity alleles (FCGRIIA HH/HR) and patients with low
affinity alleles (FCGRIIA RR) (Tables 1 and 2). However,
there was a trend to a better response among patients
with high affinity alleles.
Conclusion
These results suggest that FCGR IIA-H131R polymorph-
ism has low influence in the clinical efficacy of anti-TNF
therapies in patients with psoriatic arthritis. Although
different to previously reported results in rheumatoid
arthritis [1], these results can be explained because of
the better and more prolonged response to anti-TNF
therapy in psoriatic arthritis than in rheumatoid arthri-
tis. In addition, in this study we analyzed patients with
three different anti-TNF-alpha therapies.
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Table 1 12 weeks EULAR Response FCGRIIA
HH+HR RR Total
Null (%) 10.1 26.3 13.3
Moderate (%) 27.8 10.5 24.5
Good (%) 62.0 63.2 62.2
p = 0.086.
Table 2 24 weeks EULAR response FCGRIIA
HH+HR RR Total
Null (%) 8.9 26.3 13.3
Moderate (%) 27.8 15.8 25.5
Good (%) 63.3 57.9 62.2
p = 0.090.
Ramirez et al. Journal of Translational Medicine 2010, 8(Suppl 1):P38
http://www.translational-medicine.com/content/8/S1/P38
© 2010 Ramirez et al; licensee BioMed Central Ltd.Author details
1Rheumatology, Hospital Clinic, Barcelona, Spain.
2Immunology, Hospital
Clinic, Barcelona, Spain.
3Hospital Clinic, Barcelona, Spain.
4Rheumatology,
Complejo Hospitalario Juan Canalejo, La Coruña, Spain.
Published: 25 November 2010
Reference
1. Cañete JD, et al: . Ann Rheum Dis. 2009, 68:1547-52.
doi:10.1186/1479-5876-8-S1-P38
Cite this article as: Ramirez et al.: Influence of variants of Fcg receptor
IIA on the European league against rheumatism responses to anti-
tumour necrosis factor alpha therapy in psoriatic arthritis. Journal of
Translational Medicine 2010 8(Suppl 1):P38.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramirez et al. Journal of Translational Medicine 2010, 8(Suppl 1):P38
http://www.translational-medicine.com/content/8/S1/P38
Page 2 of 2